CEPT Inhibitors Finally Show Potential With Obicetrapib
Adding the cholesteryl ester transfer protein (CETP) inhibitor obicetrapib to high-intensity statins significantly lowers cholesterol levels and substantially increases the number of patients achieving cholesterol targets, suggest data from the ROSE trial.

A trial comparing two doses of obicetrapib with placebo in 120 patients already on high-intensity statin therapy has shown that it significantly reduces low-density-lipoprotein (LDL) cholesterol by up to 51% over baseline and improves many other lipid parameters. The drug was also associated with up to 82.5% of patients achieved an LDL cholesterol target of 55 mg/dL to 70 mg/dL, all while being well tolerated.
They were randomized in a 1:1:1 ratio to obicetrapib 5 mg or 10 mg or placebo, and were assessed at baseline and weeks 4, 8, 12, 16, and 23.

Of 195 patients, 120 were randomized, and all but one completed treatment. Mean age of the study cohort was 61.1 to 62.9 years, and between 35.7% and 52.5% of participants were female. Mean baseline LDL-cholesterol levels ranged from 88.0 mg/dL to 95.0 mg/dL. Compared with baseline, the addition of obicetrapib 5 mg to high-intensity statin therapy reduced LDL-cholesterol levels by 42%, whereas the addition of obicetrapib 10 mg was associated with median reductions of 51%. Both reductions were significantly greater than the 7% reduction with placebo (P < .0001 for both).

Patients taking the lower dose of obicetrapib also saw reductions in their apolipoprotein (apo)B levels, compared with baseline, of 24%, which increased to 30% with the higher dose, compared with 3% for placebo. Reductions in non-high-density-lipoprotein (HDL)-cholesterol levels were 39%, 44%, and 4% respectively. Lipoprotein(a) levels fell by a median of 33.8%, compared with baseline, in patients in the obicetrapib 5 mg group and by 56.5% in those in the 10 mg group; in the placebo group, levels remained unchanged.
Triglycerides also were reduced by a median of 11%, compared with baseline, with obicetrapib 5 mg and by 8% with obicetrapib 10 mg, but rose by 2% with placebo.

In contrast, HDL-cholesterol levels increased by a median of 135%, compared with baseline, with obicetrapib 5 mg and by 165% with obicetrapib 10 mg; in contrast, levels decreased by 5% with placebo.

Source: https://www.medscape.com/viewarticle/974786?src=rss